On February 26, 2025 Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, reported the successful enrollment of the sixth patient into the safety lead-in cohort of its ongoing Phase 2 trial evaluating Radspherin for the treatment of peritoneal carcinomatosis from ovarian cancer (Press release, Oncoinvent, FEB 26, 2025, https://www.oncoinvent.com/press-release/oncoinvent-asa-reports-completed-inclusion-in-the-initial-safety-lead-in-cohort-of-the-phase-2-trial-of-radspherin-in-ovarian-cancer-patients/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet [SID1234650649]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Radspherin is a novel alpha-radiation therapy designed for targeted, direct treatment of cancers that have spread to body cavities. The Phase 2 is a randomised, open label, multicentre trial (NCT06504147) assessing the efficacy and safety of Radspherin in patients with peritoneal metastases from ovarian cancer following complete surgical resection and pre-operative chemotherapy.
The initial safety lead-in is designed to evaluate the safety and tolerability of Radspherin at the recommended dose of 7 MBq in the trial population before expanding to enrollment in the randomized part of the trial.
"The completion of patient recruitment in the safety lead-in marks an important milestone in the advancement of our Phase 2 trial," said Oystein Soug, CEO of Oncoinvent. "We are encouraged by being able to recruit patients and ship Radspherin to centers in the US, UK, EU as well as Norway in this trial. We will now analyze the safety data, announce the findings during March and we subsequently expect to move ahead with full trial enrollment. This milestone further reinforces our commitment to developing Radspherin as a promising treatment option for patients with peritoneal carcinomatosis."